FDA clears Pear's app for opioid use disorder

FDA granted market clearance to reSET-O, a prescription digital therapeutic from Pear Therapeutics Inc. (Boston, Mass.) and Sandoz, to treat opioid use disorder. Sandoz plans to launch reSET-O, which is to be used in conjunction with outpatient clinician-delivered care, in the coming days.

Pear and Sandoz launched reSET, the first FDA-authorized prescription digital therapeutic, for substance use disorder last month. The companies partnered in April to develop reSET and reSET-O (see "Pear, Sandoz Launch First FDA-Approved Digital Therapeutic")...